Journal
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY
Volume 9, Issue 12, Pages 2036-2040Publisher
WILEY
DOI: 10.1002/acn3.51684
Keywords
-
Categories
Funding
- Australian National Health and Medical Research Council (NHMRC) Centre for Research Excellence Grant [GNT2006841]
- NHMRC Synergy Grant [GNT2010562]
- NHMRC Senior Investigator Fellowship [GNT1172897]
Ask authors/readers for more resources
Although anti-seizure medications that block sodium channels are generally not recommended for Dravet syndrome, there is ongoing debate about the use of the sodium-channel blocker phenytoin, which is commonly used to treat status epilepticus in Dravet syndrome patients. This study reports four cases of Dravet syndrome patients who experienced a reduction in seizure frequency and duration with long-term phenytoin therapy. In two patients, phenytoin resulted in prolonged periods without status epilepticus for the first time. Attempts to discontinue phenytoin in all patients after 1 to 20 years of use led to worsened seizure control. Reintroducing phenytoin improved seizure control, suggesting its potential benefits in certain Dravet syndrome patients.
Anti-seizure medications that block sodium channels are generally considered contraindicated in Dravet syndrome. There is, however, considerable debate about the sodium-channel blocker phenytoin, which is often used for status epilepticus, a frequent feature of Dravet syndrome. We describe four patients with Dravet syndrome in whom long-term phenytoin therapy reduced seizure frequency and duration. In two patients, phenytoin produced prolonged periods without status epilepticus for the first time. Attempting to wean phenytoin in all patients after 1 to 20 years of use resulted in seizure exacerbation. Reintroducing phenytoin improved seizure control, suggesting phenytoin is beneficial in some patients with Dravet syndrome.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available